RxDoctor Payments Data

Swetha Murthi

Endocrinology, Diabetes & Metabolism · Yuma, AZNPI 1588028484

Payments from drug & device makers

$390in general payments, 2019–2025

Across 20 payments — averaging $19.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Radius Health, Inc.$88
  • Tandem Diabetes Care, Inc.$70
  • Astellas Pharma US Inc$46
  • Boehringer Ingelheim$32
  • GSK$30
  • Medtronic$25
  • plus $99 from 5 others

What the payments were for

  • Food & beverage$390100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$390 in reported general payments places this provider in the 25th percentile of 148 endocrinology, diabetes & metabolism providers in Arizona.

See all endocrinology, diabetes & metabolism providers in Arizona

Medicare billing

Part B allowed, 2024
$63,804
Medicare patients
270
Services billed
744

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide332$405,713
OzempicSemaglutide221$260,716
JanuviaSitagliptin Phosphate119$116,287
JardianceEmpagliflozin135$115,539
MounjaroTirzepatide49$60,221
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog102$56,611
FarxigaDapagliflozin Propanediol49$54,516
Humulin R U-500 KwikpenInsulin Regular, Human12$38,237
Tresiba Flextouch U-100Insulin Degludec35$31,709
Victoza 3-PakLiraglutide21$28,600
Lantus SolostarInsulin Glargine,hum.Rec.Anlog155$28,060
TradjentaLinagliptin26$20,217
RybelsusSemaglutide18$16,817
Humalog Kwikpen U-100Insulin Lispro62$15,337
Insulin Lispro Kwikpen U-100Insulin Lispro47$12,206

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus, Novolog$21$285,081271 claims
Boehringer IngelheimJardiance, Tradjenta$32$135,756161 claims
AstraZenecaFarxiga$19$54,51649 claims
AbbVieSynthroid$21$7,81793 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 148 endocrinology, diabetes & metabolism providers in Arizona.

Other endocrinology, diabetes & metabolism in Yuma

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →